Fierce Biotech1d
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
BioSpace16h
OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
Opko Health, Entera Bio enter collaboration agreement for GLP-1/glucagon peptide
OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...